Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

In view of advances in early detection and treatment, the 5-year relative survival rate for all cancer patients combined is now approximately 66%. As a result, there are more than 13.7 million cancer survivors in the United States, with this number increasing by 2% annually. For many patients, improvements in survival have been countered by therapy-associated adverse effects that may seriously impair long-term functional status, workplace productivity, and quality of life. Approximately 20% to 40% of cancer patients given neurotoxic chemotherapy develop chemotherapy-induced peripheral neurotoxicity (CIPN), which represents one of the most common and potentially permanent nonhematologic side effects of chemotherapy. Permanent bilateral hearing loss and/or tinnitus can result from several ototoxic therapies, including cisplatin- or carboplatin-based chemotherapy. CIPN and ototoxicity represent important challenges because of the lack of means for effective prevention, mitigation, or a priori identification of high-risk patients, and few studies have applied modern genomic approaches to understand underlying mechanisms/pathways. Translational genomics, including cell-based models, now offer opportunities to make inroads for the first time to develop preventive and interventional strategies for CIPN, ototoxicity, and other treatment-related complications. This commentary provides current perspective on a successful research strategy, with a focus on cisplatin, developed by an experienced, transdisciplinary group of researchers and clinicians, representing pharmacogenomics, statistical genetics, neurology, hearing science, medical oncology, epidemiology, and cancer survivorship. Principles outlined herein are applicable to the construction of research programs in translational genomics with strong clinical relevance and highlight unprecedented opportunities to understand, prevent, and treat long-term treatment-related morbidities.

[1]  M. Stovall,et al.  Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. , 2003, JAMA.

[2]  A. Lluch,et al.  Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. , 2010, Cancer treatment reviews.

[3]  Judy H. Cho,et al.  Finding the missing heritability of complex diseases , 2009, Nature.

[4]  P. Visscher,et al.  Estimating missing heritability for disease from genome-wide association studies. , 2011, American journal of human genetics.

[5]  M. Dolan,et al.  Regulatory Polymorphisms in b-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy , 2012 .

[6]  J. Schellens,et al.  Relationship between cisplatin administration and the development of ototoxicity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Hayden,et al.  Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children , 2013, Clinical pharmacology and therapeutics.

[8]  L. Einhorn,et al.  Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Hall,et al.  Risk of leukemia after platinum-based chemotherapy for ovarian cancer. , 1999, The New England journal of medicine.

[10]  R. Klein,et al.  Cigarette smoking and hearing loss: the epidemiology of hearing loss study. , 1998, JAMA.

[11]  D. Bajorin.  The graying of testis cancer patients: what have we learned? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Krarup,et al.  Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study , 1999, Neuropathology and applied neurobiology.

[13]  A. Bleasel,et al.  Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Ulrich,et al.  Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. , 2013, Journal of the National Cancer Institute.

[15]  M. Hayden,et al.  Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy , 2013, Nature Genetics.

[16]  T. Merchant,et al.  Auditory Late Effects of Childhood Cancer Therapy: A Report From the Children's Oncology Group , 2010, Pediatrics.

[17]  A. Ng,et al.  Secondary malignancies across the age spectrum. , 2010, Seminars in radiation oncology.

[18]  M. Dolan,et al.  Relating human genetic variation to variation in drug responses. , 2012, Trends in genetics : TIG.

[19]  M. Louwman,et al.  Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Hartung,et al.  Chemotherapy-induced peripheral neuropathy , 2002, Journal of Neurology.

[21]  L. Davis,et al.  Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies , 1984, Cancer.

[22]  G. Smoorenburg,et al.  Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration. A quantitative histological study , 2004, Hearing Research.

[23]  J. Turner,et al.  Short Interfering RNA against Transient Receptor Potential Vanilloid 1 Attenuates Cisplatin-Induced Hearing Loss in the Rat , 2008, The Journal of Neuroscience.

[24]  Clive E. Bowman,et al.  Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions , 2009, The Pharmacogenomics Journal.

[25]  S. Fosså,et al.  Scale for Chemotherapy-induced Long-term Neurotoxicity (SCIN): Psychometrics, Validation, and Findings in a Large Sample of Testicular Cancer Survivors , 2006, Quality of Life Research.

[26]  P. Hall,et al.  Treatment-associated leukemia following testicular cancer. , 2000, Journal of the National Cancer Institute.

[27]  C. Fowler,et al.  Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis , 2001, British Journal of Cancer.

[28]  S. Bhatia.  Role of Genetic Susceptibility in Development of Treatment-Related Adverse Outcomes in Cancer Survivors , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[29]  P. Sterk,et al.  Long-term effects of chemotherapy in patients with testicular cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Pui,et al.  Second malignant neoplasms and cardiovascular disease following radiotherapy. , 2012, Journal of the National Cancer Institute.

[31]  Wei Zhang,et al.  Genome-Wide Variation of Cytosine Modifications Between European and African Populations and the Implications for Complex Traits , 2013, Genetics.

[32]  Tyson A. Clark,et al.  Genetic architecture of transcript-level variation in humans. , 2008, American journal of human genetics.

[33]  D. McBride,et al.  Audiometric notch as a sign of noise induced hearing loss , 2001, Occupational and environmental medicine.

[34]  S Williams,et al.  Characteristics of the audiometric notch as a clinical sign of noise exposure , 2001, Scandinavian audiology.

[35]  E. Gamazon,et al.  Clinical Translation of Cell‐Based Pharmacogenomic Discovery , 2012, Clinical pharmacology and therapeutics.

[36]  L. Kanz,et al.  Analysis of Risk Factors for Cisplatin-Induced Ototoxicity in Patients With Testicular Cancer , 1998 .

[37]  N J Cox,et al.  The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics , 2012, Clinical pharmacology and therapeutics.

[38]  G. Armstrong,et al.  Clinical ascertainment of health outcomes among adults treated for childhood cancer. , 2013, JAMA.

[39]  M. Schell,et al.  Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Koltzenburg,et al.  Chemotherapy‐induced peripheral neurotoxicity: A critical analysis , 2013, CA: a cancer journal for clinicians.

[41]  J. Ahn,et al.  Treatment outcomes and clinicopathologic characteristics of triple‐negative breast cancer patients who received platinum‐containing chemotherapy , 2009, International journal of cancer.

[42]  D. Ekwueme,et al.  Years of potential life lost and productivity losses from male urogenital cancer deaths--United States, 2004. , 2010, Urology.

[43]  H. Jürgens,et al.  Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin , 2008, The Pharmacogenomics Journal.

[44]  J. Grem,et al.  Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer , 2005, BMC Cancer.

[45]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[46]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[47]  M. Daly,et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.

[48]  M. Dolan,et al.  Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. , 2012, Pharmacogenomics.

[49]  M. Ratain,et al.  Challenges in Interpreting the Evidence for Genetic Predictors of Ototoxicity , 2013, Clinical pharmacology and therapeutics.

[50]  John D Boice,et al.  Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.

[51]  R. Lothe,et al.  Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  F. Lieberman,et al.  Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. , 2006, Seminars in oncology.

[53]  John S Witte,et al.  Turning of COGS moves forward findings for hormonally mediated cancers , 2013, Nature Genetics.

[54]  C. Lanvers-Kaminsky,et al.  Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. , 2003, Anticancer research.

[55]  S. Duan,et al.  Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis , 2008, Pharmacogenetics and genomics.

[56]  Hae Kyung Im,et al.  Poly‐Omic Prediction of Complex Traits: OmicKriging , 2013, Genetic epidemiology.

[57]  E. Gamazon,et al.  Genome-wide Meta-analysis Identifies Variants Associated with Platinating Agent Susceptibility Across Populations , 2011, The Pharmacogenomics Journal.

[58]  D. Eddins,et al.  Presbycusis phenotypes form a heterogeneous continuum when ordered by degree and configuration of hearing loss , 2010, Hearing Research.

[59]  F. Li,et al.  Long-term survivors of cancer. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[60]  Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. , 2001 .

[61]  M. Relling,et al.  The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin‐Induced Ototoxicity in Children With Cancer , 2013, Clinical pharmacology and therapeutics.

[62]  S. Fosså,et al.  Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors , 2009, Journal of the National Cancer Institute.

[63]  S. Isakoff,et al.  Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents , 2010, Cancer journal.

[64]  A. Windebank,et al.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. , 2012, Neuro-oncology.

[65]  John D Boice,et al.  Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. , 2002, Journal of the National Cancer Institute.

[66]  K. Knight,et al.  Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  D. Stewart,et al.  Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  A. am Zehnhoff-Dinnesen,et al.  Understanding platinum-induced ototoxicity. , 2013, Trends in pharmacological sciences.

[69]  Yusuke Nakamura,et al.  A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 , 2012, Clinical Cancer Research.

[70]  S. Palmer,et al.  Cardiovascular risk in long‐term survivors of testicular cancer , 2008, Cancer.

[71]  D P Dearnaley,et al.  Cardiovascular disease as a long-term complication of treatment for testicular cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  Marisa Wong Medina,et al.  Pharmacogenomic Discovery Using Cell-Based Models , 2009, Pharmacological Reviews.

[73]  J. Schacht,et al.  Glutathione S-transferases in the organ of Corti of the rat: Enzymatic activity, subunit composition and immunohistochemical localization , 1993, Hearing Research.

[74]  A. Mohar-Betancourt,et al.  TOXICITY PREVENTION WITH AMIFOSTINE IN PEDIATRIC OSTEOSARCOMA PATIENTS TREATED WITH CISPLATIN AND DOXORUBICIN , 2007, Pediatric hematology and oncology.

[75]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[76]  G. Altavilla,et al.  The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[77]  S. Kry,et al.  Radiation Dose and Breast Cancer Risk in the Childhood Cancer Survivor Study , 2010 .

[78]  G. Cavaletti,et al.  Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. , 2010, European journal of cancer.

[79]  S. M. de la Monte,et al.  Alcohol‐related peripheral neuropathy: Nutritional, toxic, or both? , 2011, Muscle & nerve.

[80]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[81]  J. Stockman.  Cancer Risk Among Patients With Myotonic Muscular Dystrophy , 2013 .

[82]  G. Smoorenburg,et al.  The cochlear targets of cisplatin: An electrophysiological and morphological time-sequence study , 2005, Hearing Research.

[83]  C. Bokemeyer,et al.  Evaluation of long-term toxicity after chemotherapy for testicular cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  F. Martinez,et al.  Drug-induced Otoxicity: Current Status , 2001 .

[85]  S. Fosså,et al.  Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  Ivo D. Shterev,et al.  Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy , 2012, Clinical Cancer Research.

[87]  S. Fosså,et al.  Second malignant neoplasms in testicular cancer survivors. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[88]  R. Lothe,et al.  Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study , 2007, Journal of Translational Medicine.

[89]  G. Cavaletti,et al.  Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. , 2011, The Lancet. Oncology.

[90]  A. Ng,et al.  Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors , 2013, Nature Reviews Clinical Oncology.

[91]  B. Wolffenbuttel,et al.  The metabolic syndrome in cancer survivors. , 2010, The Lancet. Oncology.

[92]  L. Travis,et al.  The Epidemiology of Second Primary Cancers , 2006, Cancer Epidemiology Biomarkers & Prevention.

[93]  W. Trojaborg,et al.  Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  H. Jürgens,et al.  Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin , 2000, Anti-cancer drugs.

[95]  I. Bodrogi,et al.  Characteristics and Risk Factors of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients Detected by Distorsion Product Otoacoustic Emission , 2006, Oncology.

[96]  Guido Cavaletti,et al.  Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. , 2012, Critical reviews in oncology/hematology.

[97]  E. Yeh,et al.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.

[98]  M. Dolan,et al.  Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy , 2012, Clinical Cancer Research.

[99]  W. London,et al.  Amifostine does not protect against the ototoxicity of high‐dose cisplatin combined with etoposide and bleomycin in pediatric germ‐cell tumors , 2005, Cancer.

[100]  L. Rybak.  Mechanisms of cisplatin ototoxicity and progress in otoprotection , 2007, Current opinion in otolaryngology & head and neck surgery.

[101]  T. Lancet.  Cancer survivors: living longer, and now, better , 2004, The Lancet.

[102]  B. Spiegelman,et al.  Molecular mechanisms of cancer development in obesity , 2011, Nature Reviews Cancer.

[103]  C. Stiller,et al.  Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. , 2011, JAMA.

[104]  H. Goldschmidt,et al.  Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. , 2010, The Lancet. Oncology.

[105]  D. Leroith,et al.  The Link between the Metabolic Syndrome and Cancer , 2011, International journal of biological sciences.

[106]  M. Enjoji,et al.  Angioleiomyoma. A clinicopathologic reappraisal of 562 cases , 1984, Cancer.

[107]  L. Einhorn,et al.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. , 1977, Annals of internal medicine.

[108]  A. Smit,et al.  Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  D. Dearnaley,et al.  Long‐term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer , 2010, Cancer.

[110]  E. C. van Dalen,et al.  Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. , 2016, The Cochrane database of systematic reviews.

[111]  P. Okunieff,et al.  Commentary Testicular Cancer Survivorship: Research Strategies and Recommendations , 2022 .

[112]  A. Tichelli,et al.  Considerations for adult cancer survivors. , 2005, Hematology. American Society of Hematology. Education Program.

[113]  Jason H. Moore,et al.  Missing heritability and strategies for finding the underlying causes of complex disease , 2010, Nature Reviews Genetics.

[114]  S. Fosså,et al.  Components of the metabolic syndrome in long-term survivors of testicular cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[115]  A. Khrunin,et al.  Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients , 2010, The Pharmacogenomics Journal.

[116]  J. Albers,et al.  Interventions for preventing neuropathy caused by cisplatin and related compounds. , 2007, The Cochrane database of systematic reviews.

[117]  Yingchun Zhao,et al.  Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. , 2012, Lung cancer.

[118]  John D Boice,et al.  The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  E. Gamazon,et al.  Population differences in microRNA expression and biological implications , 2011, RNA biology.

[120]  A. Knight,et al.  Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity , 2005, Neurobiology of Disease.

[121]  P. Novotny,et al.  Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy , 2002, Pain.

[122]  J. Stockman,et al.  Chronic Health Conditions in Adult Survivors of Childhood Cancer , 2008 .

[123]  J. Glick,et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  A. Mykletun,et al.  Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  S. W. Hansen,et al.  The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[126]  G. Cavaletti,et al.  Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. , 1999, Neurotoxicology.

[127]  C. Metayer,et al.  “Second Malignant Neoplasms Among Long-Term Survivors of Hodgkinʼs Disease: A Population-Based Evaluation Over 25 Years” , 2002 .

[128]  D. Kerr,et al.  Long-term sequelae of treatment for testicular germ cell tumours. , 1990, British Journal of Cancer.

[129]  C. Shapiro,et al.  Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. , 2013, JAMA.

[130]  M. Relling,et al.  Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.